Bodor Laboratories Inc. Announces FDA Approval of SofdraTM for primary axillary hyperhidrosis
Miami, FL, June 25, 2024 – Bodor Laboratories Inc., a leading pharmaceutical research and development company, is pleased to announce that its licensee, Botanix, an Australia- and Pennsylvania-based pharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for SofdraTM (sofpironium) topical gel, 12.45% for the treatment of primary axillary hyperhidrosis (excessive […]
Bodor Laboratories Inc. Announces Leadership Evolution with Erik Bodor as CEO and Highlights Milestones in Sofpironium Bromide Development
Menu Home Research & Development Pipeline The Science Recent Publications Selected Patents Company About Who We Are Partners News Contact Us Bodor Laboratories Inc. Announces Leadership Evolution with Erik Bodor as CEO and Highlights Milestones in Sofpironium Bromide Development Miami, FL, April 3, 2024 – Bodor Laboratories Inc. (BLI), a leader in innovative pharmaceutical research […]
Bodor Laboratories Inc. Congratulates Kaken Pharmaceutical on Partnership with Dong Wha Pharmaceutical for Marketing Sofpironium Bromide in Korea
Menu Home Research & Development Pipeline The Science Recent Publications Selected Patents Company About Who We Are Partners News Contact Us Bodor Laboratories Inc. Congratulates Kaken Pharmaceutical on Partnership with Dong Wha Pharmaceutical for Marketing Sofpironium Bromide in Korea Miami, FL, June 23, 2023 – Bodor Laboratories Inc., a privately held pharmaceutical research and development […]
Enhanced Activity of Topical Hydrocortisone by Competitive Binding of Corticosteroid-Binding Globulin
Atopic dermatitis of sensitive areas such as the face, particularly in children, is a difficult disease to treat as the standard therapeutic, topical steroids, is contraindicated for this application in children. Hydrocortisone (HC) can be used in these instances because it has been shown to be safe, but is often ineffective as it is a […]
Identification of esterase involved in the metabolism of two corticosteroid soft drugs
Abstract The soft drug approach is successful in obtaining high local therapeutic efficacy without systemic adverse effects, because soft drugs are designed to be bioconverted to inactive form by hydrolytic enzymes in systemic circulation. However, there is little information about the exact nature of these metabolic enzymes. In this study, the human enzymes for biotransformation of soft drugs were […]
Potent analogues of etiprednol dicloacetate, a second generation of soft corticosteroids†
†This paper is dedicated to Prof. Yuichi Sugiyama, Head of the Sugiyama Laboratory at RIKEN Innovation Center (Yokohama, Japan), in recognition of his 70th birthday. Abstract Objectives Loteprednol etabonate (LE) is the first, highly successful soft corticosteroid (SC) designed using the ‘inactive metabolite’ approach, starting with ∆1-cortienic acid (d-CA). The next generation of SCs […]